Next Article in Journal
Structural Modifications of Nature-Inspired Indoloquinolines: A Mini Review of Their Potential Antiproliferative Activity
Next Article in Special Issue
Antiproliferative Benzoindazolequinones as Potential Cyclooxygenase-2 Inhibitors
Previous Article in Journal
One-step Preparation of a VHH-based Immunoadsorbent for the Extracorporeal Removal of β2-microglobulin
Previous Article in Special Issue
Synthesis, X-ray Analysis, Biological Evaluation and Molecular Docking Study of New Thiazoline Derivatives
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 24
Issue 11
10.3390/molecules24112120
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

The Methylene-Cycloalkylacetate (MCA) Scaffold in Terpenyl Compounds with Potential Pharmacological Activities

by
Ignacio E. Tobal
†,
Alejandro M. Roncero
†,
Rosalina F. Moro
,
David Díez
and
Isidro S. Marcos
*
Departamento de Química Orgánica, Facultad de Ciencias Químicas, Universidad de Salamanca. Plaza de los Caídos 1-5, 37008 Salamanca, Spain
*
Author to whom correspondence should be addressed.
†
These authors have contributed equally to this work.
Molecules 2019, 24(11), 2120; https://doi.org/10.3390/molecules24112120
Submission received: 22 May 2019 / Revised: 3 June 2019 / Accepted: 3 June 2019 / Published: 5 June 2019
(This article belongs to the Special Issue Application of Organic Synthesis to Bioactive Compounds)
Browse Figures
Review Reports Versions Notes

Abstract

:
Recently, the methylene-cycloakylacetate (MCA) scaffold has been reported as a potential pharmacophore for neurite outgrowth activity. In this work, natural diterpenes that embed MCA fragments are reviewed, as they are major components of Halimium viscosum: ent-halimic acid, the prototype for these bioactive compounds. Herein, structures, sources, and activities for the natural diterpenes, as well as their synthetic derivatives of interest, are reviewed.

Graphical Abstract

1. Halimanes Containing the MCA Fragment

Recently, molecules containing methylene-cycloalkylacetate (MCA) fragments (Figure 1) have been reported to show very interesting neurotrophic properties [1]. The MCA scaffold can be observed in many easily available terpenes of natural origin and synthetic derivatives, many of which show interesting pharmacological activities [2,3,4,5,6].
Although different terpenoids containing the MCA scaffold have been reported, in this work only the natural diterpenoids will be reviewed. Among diterpenoids containing the MCA fragment, halimane is the most structurally diverse and numerous family.
As the MCA moiety can be considered as a pharmacophore for neurotrophic activity, these natural diterpenoids could be understood as novel neurotrophic lead compounds, but show other interesting biological (e.g., antitumor and antifeedant) activities [7,8].
Firstly, halimane diterpenoids, with an MCA fragment embedded, with eventually potential neurotrophic activity and other biological activities are discussed. They have been classified into three groups according to the annular double bond found: in Ring A, Group I (Figure 2), in Ring B, Group II (Figure 3), or, as secoderivatives, in Group III (Figure 4). The compounds of each group have been included in Table 1, Table 2 and Table 3, respectively, where the natural source, the biological activity (if studied), and references are given. As can be observed in Group I (Table 1), nearly all are ent-halimanes and degraded compounds such as di-, tri-, and tetranorderivatives. Group II contains halimanes from the normal and enantiomeric series. All the secoderivatives, the Group III compounds, correspond to the enantiomeric series. All compounds have been isolated from plants of different families, and only two of them have been found in microorganisms—bacteria of the genus Micromonospora.

1.1. Group I: The Halim-1(10)-Enes Group

This group is composed of 46 ent-halimanes 1–46 and a halimane 47 (Figure 2). All of them have a carboxylic function at C18, except 40 and 41 where the function appears at C19 as a hydroxyl group or a carbocyclic acid. This group contains compounds such as chettaphanin I, 1, the first halimane known, and ent-halimic acid, characterized as its methyl ester, 2, from which the group attains its name, and which has been used as a starting material to establish the absolute configuration of chettaphanin I, 1, and for the synthesis of many ent-halimanes, as will be discussed later on.

1.2. Group II: The Halim-5-Enes Group

This group contains 30 compounds (Figure 3). Nine of them (48–56) belong to the enantiomeric series called ent-halimanes, two of which are nor-ent-halimanes, and the rest of the halimanes belong to the normal series (57–77), among which six 8-epi-halimanes (72–77) can be found, where three are tetranorderivatives (75–77).

1.3. Group III: Secohalimanes and 4-Enes Derivatives

All secohalimanes (78–89) that contain the MCA fragment are 3-seco derivatives (Figure 4). All of them contain a furan fragment in the side chain and four present a butan-20,12-olide. The only halim-4-en derivative is a norderivative known as teucvin or mallotucin A, 89.

2. Ent-Halimic Acid as a Precursor of Biologically Active Compounds and Other Derivatives of Interest

Ent-halimic acid is very abundant in the Halimium viscosum extract, and its methyl ester 2 has been used as a starting material for the synthesis of a series of natural halimanes corroborating their structures, biologically active derivatives and the preparation of other interesting compounds. Figure 5 shows some of the diterpene or sesquiterpene derivatives synthesized from ent-halimic acid: 1. ent-halimanolides [2,56,57,58]; 2. chettaphanin I and II [4,5]; 3. sesterterpenolides [6,59,60]. Figure 6 shows other groups of compounds prepared from 2, among which are as follows: 4. hybrid compounds: sesterterpenolide bioconjugates and glycerophospholipids [61]; 5. rearranged derivatives: ent-labdanes [62], abeopicrasanes [63], and a propellane [64]; 6. sequiterpene-quinone/hidroquinones [65]; 7. terpene alkaloids: sesqui- and diterpene-alkaloids [7,8,66,67,68,69].

3. Synthetic Transformations of Ent-halimic Acid Methyl Ester, 2

In this section, the synthesis of these compounds is discussed. The synthetic routes starting from ent-halimic acid methyl ester 2 have made it possible to establish or corroborate the structure of different natural ent-halimanes and access other interesting derivatives due to their rearranged structures or to their biological activities. Many of the synthesized intermediates possess the MCA fragment in their structures.

3.1. Synthesis of Ent-Halimanolides

The first three natural ent-halimanolides 90, 91 and 92 were synthesized from ent-halimic acid using the methyl ketone 94 as intermediate [2,56] (Scheme 1). This methyl ketone 94 was obtained from ent-halimic acid methyl ester 2 by a six-step procedure that includes reduction of the methoxycarbonyl at C18. Bestmann methodology was used for the synthesis of butenolide 96 [70], the key intermediate in the synthesis of ent-halimanolides 90, 91, and 92. The decalin double bond isomerization of 96 to the tetrasubstituted position permits the synthesis of 90. The γ-hydroxybutenolides 91 and 92 can be obtained using Boukouvalas methodology [71]. Biological testing has been carried out on these compounds. The compound 96 shows cytotoxic and antiviral activity [HELAM cells (IC50 = 5.0), MDCK (IC50 = 5.1) and influenza virus (IC50 = 6.8)] [56].
Due to the biological (antifeedant, anti-inflammatory, antitumor, and antimicrobial) activity related to diterpenoids and sesterterpenoids containing the hydroxybutenolide scaffold, a synthesis of ent-halimanolides, structurally related to natural occurring lactones, was designed, starting from ent-halimic acid (α and β-hydroxybutenolides: 15,16-olides 97–100 and 16,15-olides 101–104) [58]. The key intermediate, triol 106 (Scheme 2), was obtained by selective photooxygenation and ulterior hydroboration. The selective protection of 106 as 1,3-dioxolane or 1,3-dioxane led to the hydroxyderivatives 107 and 108, respectively, after oxidation and deprotection of which produced the β-hydroxybutanolides 97–100 (in a ratio 27:33:20:20) and the α-hydroxybutanolides 101–104 (in a ratio 22:22:28:28), respectively. The relative configuration of these compounds was established by 1H NMR, and the absolute configuration achieved by CD spectroscopy. The structures of 100 and 103 were confirmed via X-ray. Lactone 109 was synthesized by a 5-step sequence using methylketone 110 as an intermediate [29]. Using Reformatsky methodology [72,73], β-hydroxybutanolides 109 was obtained. Antifeedant testing has been carried out on these compounds. The α-hydroxybutanolides 103 and 104 are weakly active, and β-hydroxybutanolides 109 are moderately active [58].
In the same manner, an efficient synthesis of the ent-halimanolide 112 (15,16-epoxy-12-oxo-ent-halima-5(10),13(16),14-trien-18,2β-olide), from ent-halimic acid, has been achieved, corroborating the structure of the natural compound and establishing its absolute configuration [57] (Scheme 3).
By using the dinorderivatives 113 and 114 as intermediates, the tetranorderivative 116 was accessed by a new route at the multigram scale. From 116, by a six-step sequence, the natural lactone 112, moderately active against HeLa (human cervix cancer), was obtained [57]

3.2. Chettaphanin Synthesis

Chettaphanins I, 1, and II, 123, isolated from Adenochlaena siammensis Ridl (Euphorbiaceae) in 1970 [9] and 1971 [10] are the first two ent-halimanes discovered. Both compounds are the main components of “chettaphangki,” a digestive remedy used in folk medicine in Thailand. Their structures have been determined by chemical and spectroscopic correlations. The chettaphanin II structure was corroborated by X-ray crystallography of a chettaphanin II derivative. The absolute configuration that remained undetermined was established by synthesis using ent-halimic acid as a starting material [4,5] (Scheme 4). The key intermediate 125 was accessed from ent-halimic acid methyl ester 2 by a seven-step sequence, with good global yield. This sequence includes, side chain degradation to the corresponding dinorderivative followed by C2 functionalization and Baeyer–Villiger oxidation until the corresponding tetranorderivative 124 was obtained. The protection of enone 124 was followed by hydrolysis of the acetoxyl group and oxidation, leading to aldehyde 125. During the enone protection with ethylene glycol, the dioxolane formed, and the isomerization of the double bond to the decalin tetrasubstituted position took place at the same time. Furyllithium addition to 125 followed by oxidation led to intermediate 126. Chettaphanin II, 123, was obtained by a simple treatment in acidic media of 126, and chettaphanin I, 1, was obtained by epoxidation of 126, followed by treatment in acidic media.

3.3. Sesterterpenolide Synthesis

Several sesterterpenoids isolated from marine natural sources contain a residue of γhydroxybutenolide as a characteristic structural fragment. This fragment is responsible in many cases for the bioactivity of the corresponding sesterterpenolides.
Cladocorans A and B, isolated from the mediterranean coral6 Cladocora cespitosa (L) by Fontana et al. [74] (Figure 7), are sesterterpenolides, and their structures, 127 and 128, were established according to their spectroscopic properties. These sesterterpenolides are structural analogues of the natural dysidiolide [75,76], an inhibitor of protein phosphatases cdc25A (IC50 = 9.4 μM) and cdc25B (IC50 = 87 μM), which are essential for cell proliferation. Dysidiolide inhibits the growth of A-549 human lung carcinoma and P388 murine leukaemia cell lines at low micromolar concentrations [77,78,79,80,81]. These important physiological activities of the dysidiolide attract the attention of chemists, biologists, and pharmacologists. Compounds 127 and 128 can be considered as isoprenyl-halimanes and their potential biological activities inspired us to synthesize them with some analogues using the methyl ester of ent-halimic acid 2 as a starting material. The synthesis by our group of compounds 127 and 128 and their epimers at C18 (129 and 130) demonstrate that the structures proposed by Fontana et al. for cladocorans A and B (127 and 128) should be revised. The natural product structures for cladocorans A and B were finally revised by Miyaoka and colleagues [3] (Figure 7), and the correct structures of these natural products appear in Figure 7. It was found that cladocoran B is an olefinic regioisomer of dysidiolide, and cladocoran A is its acetate.
The synthesis of bioactive sesterterpenoid γ-hydroxybutenolides 15,18-bisepi-ent-cladocoran A and B, 127 and 128 (Scheme 5), and the epimers of these compounds at C18, 15-epi-ent-cladocoran A and B, 129 and 130, using ent-halimic acid methyl ester 2 as a starting material was achieved (Figure 7). Starting from ent-halimic acid methyl ester 2, the key intermediate 131 was accessed by a degradation sequence of the side chain of four carbon atoms and elongation of C18 by introduction of the south chain. The furosesterterpenoid 132 was obtained by introducing the furan fragment by the addition of furyllithium, and the isoprenic unit of the south chain was completed by coupling the adequate Grignard reagent with the iododerivative or the tosylderivative of 131. The corresponding epimers at C18 of 132 were separated by column chromatography. In each of them, the γ-hydroxybutenolide unit was finally obtained using Faulkner methodology [82], obtaining in each case 127, 128, 129, and 130. The synthesized sesterterpenolides 127, 128, 129, and 130 inhibited cellular proliferation (IC50 ≈ 2 µM) of a number of human leukaemic and solid tumor cell lines [60].
The promising biological activities showed that, in some cases, sesterterpenolides 127, 128, 129, and 130, dysidiolide analogues, are more active than the compound of reference dysidiolide and boost the search for new analogues. In this manner, several sesterterpenolide analogues of dysidiolides 135–139 (Scheme 6) have been synthesized from ent-halimic acid methyl ester 2, according to Scheme 6 [59]. The main structural change with the previous cladocoran derivatives is the situation of the γ-hydroxybutenolide in the south side chain of the molecule. The antitumoral activity in vitro against human HeLa, A549, HT-29, and HL-60 carcinoma cells was achieved. The proliferation inhibition data showed significant antitumor activity in the compounds 135–139, inhibiting proliferation of distinct cancer cell types with an IC50 in the low micromolar range (Scheme 6) [59].

3.4. Synthesis of Hybrid Compounds of Sesterterpenolides with Glycerols

One of the sesterterpenolides, 135, obtained from ent-halimic acid methyl ester 2 was used in the synthesis of a series of bioconjugated sesterterpenoid with phospholipids and polyunsaturated fatty acids (PUFAs) such as 141 and 142 (Figure 8), potentially bioactive compounds and antiproliferative agents in several cancer cell lines [61]. Each of the compounds that participate in these bioconjugates show antitumor activities, and a synergistic effect was expected to result from their conjugation [83,84,85]. Different substituted analogues of the original lipidic ether edelfosine [86] (1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine) were obtained while varying the sesterterpenoid in position 1 or 2 of the glycerol or a phosphocholine or PUFA unit in position 3. Simple bioconjugates of sesterterpenoids and eicosapentaenoic acid (EPA) have also been obtained. All synthetic derivatives were tested against human tumor cell lines HeLa (cervix) and MCF-7 (breast). Some compounds showed good IC50 (0.3 and 0.2 µM) values against these cell lines [61].

3.5. Synthesis of Rearranged Compounds

Due to its functionality, ent-halimic acid methyl ester 2 can be considered as an excellent synthon for the synthesis of new natural products and as a starting material in the synthesis of rearranged compounds and compounds of interest in perfumery.

3.5.1. Synthesis of Ent-Labdanes from Ent-Halimanes.

Scheme 7 shows the 1,2-shift of Me-20 of ent-halimanes (143) that leads to ent-labdanes (144). This rearrangement will be the opposite to the biosynthetic route in which the ent-labdanes are the precursors of ent-halimanes. For the first time, ent-labdanes have been synthesized starting from ent-halimic acid methyl ester 2, following a route that is the reverse of the biosynthetic one leading to the former compounds [62] (Scheme 7). Effectively, the ent-halimane epoxyderivative 143, formed in three steps from 2, led to the ent-labdane tetranorderivative 144 by treatment with Lewis acid. The rearrangement allowed the 1(10)-halimanes to be used as starting materials for the synthesis of bioactive labdanes, so this rearrangement could be used for the transformation of compounds in picrasanes with an abeopicrasane skeleton obtained from ent-halimic methyl ester 2, as will be described in the following.

3.5.2. Synthesis of Abeopicrasanes from ent-Halimanes.

Picrasanes are quassinoids and degraded triterpenes and are interesting for their antitumoral properties, bruceantin being one of the best known [87]. An advanced intermediate 147 (Scheme 8) with the ABC ring of the picrasane quassinoid skeleton 148 has been synthesized from ent-halimic acid methyl ester 2. The rearrangement from ent-halimanes to ent-labdanes previously described (Scheme 7) was thought to apply to the transformation of abeopicrasanes into picrasanes [63]. The bicyclic system of the starting material, ent-halimic acid methyl ester 2, has been incorporated as the BC part of the ABC system. To date, no diterpenes of the antipode series have been used in this kind of approach for the quassinoids with a picrasane skeleton. The tricyclic system was elaborated using the tetranorderivative 145 as an intermediate, performing the allylic oxidation and incorporating on C18 the four carbon atoms necessary to access the 4,5-secoabeopicrasane 146. The quaternary carbon C-4 was incorporated as C-10, and carbon C-5 incorporated as C-9, with the right configuration. Annulation of dione 146 led to the adequate abeopicrasane 147, exploiting the rearrangement described before.

3.5.3. Synthesis of [4.3.3] Propellanes from Ent-Halimanes.

Ent-halimic acid methyl ester 2 was used as the starting material for an efficient synthesis of a series of tetranorderivatives 149–151, functionalized at C-18 (Scheme 9). These compounds could be used to synthesize the [4.3.3] propellane 154, the oxide 152, and the lactone 153 similar to ambreinolide, all of which may be of interest to those in the perfume industry [64].

3.6. Quinone/Hydroquinone Sesquiterpenes

The quinone/hydroquinone sesquiterpenes are compounds mainly of marine origin and are interesting for their structural variety and biological activities [88]. Ent-halimic acid methyl ester 2 has been used in the synthesis of the quinone/hydroquinone sesquiterpene (-)-aureol 155, the (-)-smenoqualone 157, and the (-)-neomamanuthaquinone 156 and in the formal synthesis of the (-)-cyclosmenospongine 158 (Scheme 10) with, for example, antiinflammatory, antimicrobial, antitumor, or antiviral activities.
The syntheses of those quinone/hydroquinone sesquiterpenes 155–158 from ent-halimic acid methyl ester 2 were planned according to the synthetic sequence in Scheme 10, which was developed by the AB/ABD/ABCD approach. Effectively starting from ent-halimic acid methyl ester 2, the tetranoderivative intermediate 159 was prepared, and from this, key intermediate 160, which incorporates Ring D, was synthesized, which included a Barton decarboxylation reaction in the presence of benzoquinone [89]. The reduction of 160 and ulterior cyclization of hidroquinone 161 yielded (-)-aureol 154. The cyclization to obtain the tetracyclic compound was achieved with p-TsOH and in a stereoselective manner with F3B·Et2O. With 160 in hand, (-)-neomamanuthaquinone 156 (Scheme 10) can be obtained by the addition of NaOMe to the quinone ring, according to the procedure of Theodorakis and co-workers for the synthesis of ilimaquinone [90]. This tricyclic sesquiterpene quinone/hydroquinone, 156, give access to (-)-smenoqualone 157 and (-)-cyclosmenospongine 158.

3.7. Sesqui- and Diterpene-Alkaloids

Ent-halimic methyl ester 2 has also been used in the synthesis of terpene-alkaloids, in particular in the preparation of 7,9-dialkylpurines ((+)-agelasine C) and other diterpene- and sesquiterpene-indoles.

3.7.1. Synthesis of Diterpene-alkaloid, (+)-agelasine C [7]

Agelasines are a family of diterpene-alkaloids isolated from marine sponges of genus Agelas [91]. Agelasine C is one of the first four known agelasines, shows powerful inhibitory effects on Na and K-ATPase, and shows antimicrobial activities (Figure 9). Nakamura et al. in 1994 presented the structural formula 162 for agelasine C determined by spectroscopic methods [92]. Epi-agelasine C, 163, is an antifouling substance active against macroalgae and was isolated in 1997 by Hattori et al. [93] from the marine sponge Agelas mauritiana, whose structure was proposed by spectroscopic methods (Figure 9).
The interest in epi-agelasine C as an antifouling agent [93] and the necessity of establishing the absolute configuration led to the decision to synthesize 164 (Scheme 11). This synthesis was carried out according the synthetic strategy shown in Scheme 11, analogue to the ones developed for other agelasines, consisting in coupling the adequate terpenic fragment (165) with a purine (166) [7].
The physical properties of the synthesized product 164 are very different from the natural product epi-agelasine C, whose proposed structure of 163 (Figure 9) should be revised. On the contrary, comparing the 13C NMR spectra of 164 with agelasine C, with the proposed structure of 162, showed that they were identical to their 1H NMR spectra. Although the specific rotation for 164 and agelasine C have a similar absolute value, they have a different sign. It should be concluded that the structure for (-)-agelasine C should be corrected to the structure of 165, an enantiomer of the synthetic product 164 (+)-agelasine C (Figure 10).
Spectroscopic considerations that arose by comparison of the spectroscopic data of 164 with those of epi-agelasine C and by the specific rotation of both compounds suggested the structure that appears in Figure 10 [7] for the natural product epi-agelasine C 166.

3.7.2. Synthesis of the Indole Diterpene-alkaloid (+)-thiersindole C

The indole diterpene-alkaloid (+)-thiersindole C 167 was synthesized from ent-halimic acid methyl ester 2 [8] (Scheme 12). Firstly, the bicyclic system was elaborated by the adequate functionalization of C3, preparing intermediates 168 and 169. Secondly, a Fischer indolization was used in order to obtain the north side chain in intermediate 170, and the elongation of the south side chain with an isoprene unit was finally afforded in two steps through 171, leading to (+)-thiersindole C 167. The synthesis of (+)-thiersindole C 167 corroborated the absolute configuration of the natural product (-)-thiersindole C. The synthesized (+)-thiersindole C 167 showed antitumor activity against a number of several human tumor cell lines with an IC50 in the range of 10−5 M [8].

3.7.3. Synthesis of Sesquiterpenil-Indoles

The synthesis of 12-epi-ent-polyalthenol 172 and 12-epi-ent-pentacyclindole 174 from ent-halimic acid methyl ester 2 as starting material was carried out using the following as intermediates: the trinorderivative 175 and the trinorderivatives functionalized in C3 176-177 [66,67] (Scheme 13). The synthesis of the pentacyclic compounds can be considered biomimetic, as our group performed a cyclization of 3-(but-3-enyl) indole derivatives that produce polycyclic compounds with a hexahydrocarbazole structure. In this reaction, three stereogenic centers are generated in one step [69]. The structure of the natural product polyalthenol 178 and pentacyclindole 179 (Figure 11) were confirmed in this way.
Several of the sesquiterpene-indoles synthesized show cellular proliferation inhibition of a number of human leukaemic and solid tumor cell lines [66,67].
A series of sesquiterpene-indole (180–203 and 204–221) analogues of polyalthenol 178 and pentacyclindole 179, respectively, were synthesized (Figure 12) starting from ent-halimic acid methyl ester 2 in order to test their biological activity [68]. These 42 analogues include diverse oxidation levels at the sesquiterpenyl moiety and different functionalization on the indole ring. All derivatives were tested against a representative panel of Gram-positive and Gram-negative bacterial strains, and the human solid tumor cell lines A549 (non-small cell lung), HBL-100 (breast), HeLa (cervix), SW1573 (non-small cell lung), T-47D (breast), and WiDr (colon). Overall, the compounds presented activity against the cancer cell lines. The resulting lead, displaying a polyalthenol scaffold, showed GI50 values in the range 1.2–5.7 µM against all cell lines tested [68].

4. Conclusions

Among natural terpenoids, bicyclic diterpenes with a halimane skeleton constitute the family that most often shows the methylene-cycloalkylacetate (MCA) fragment with potential application as neurotrophic agents. Ent-halimic acid, a major constituent of Halimium viscosum, is the prototype for this MCA-containing diterpene, which has been proven to be an excellent starting material for the synthesis of a variety of biological active compounds and therefore for potentially neurotrophic diterpenes.

Author Contributions

I.S.M. designed the manuscript; I.E.T., A.M.R., R.F.M., and D.D. contributed to the manuscript writing. All authors contributed to the paper and approved the manuscript.

Funding

European Regional Development Fund (FEDER), the Spanish Ministerio de Economía y Competitividad (MINECO), Junta de Castilla y León (UIC 21), and the Universidad de Salamanca are acknowledged for their support (CTQ 2015-68175-R; AGL2016-79813-C2-2-R). IET thanks FSE (European Social Fund) and Junta de Castilla y León. AMR thanks the Ministerio de Educación for their grants.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Lankri, D.; Haham, D.; Lahiani, A.; Lazarovici, P.; Tsvelikhovsky, D. Methylene-cycloalkylacetate (MCA) scaffold-based compounds as novel neurotropic agents. ACS Chem. Neurosci. 2018, 9, 691–698. [Google Scholar] [CrossRef] [PubMed]
  2. Marcos, I.S.; Pedrero, A.B.; Sexmero, M.J.; Diez, D.; García, N.; Escola, M.A.; Basabe, P.; Conde, A.; Moro, R.F.; Urones, J.G. Synthesis of ent-Halimanolides from ent-Halimic Acid. Synthesis 2005, 19, 3301–3310. [Google Scholar] [CrossRef]
  3. Miyaoka, H.; Yamanishi, M.; Kajiwara, Y.; Yamada, Y. Total synthesis of cladocorans A and B: A structural revision. J. Nat. Prod. 2003, 68, 3476–3479. [Google Scholar]
  4. Marcos, I.S.; Hernández, F.A.; Sexmero, M.J.; Díez, D.; Basabe, P.; Pedrero, A.B.; García, N.; Sanz, F.; Urones, J.G. Synthesis and absolute configuration of (−)-chettaphanin II. Tetrahedron Lett. 2002, 43, 1243–1245. [Google Scholar] [CrossRef]
  5. Marcos, I.S.; Hernández, F.A.; Sexmero, M.J.; Díez, D.; Basabe, P.; Pedrero, A.B.; García, N.; Urones, J.G. Synthesis and absolute configuration of (−)-chettaphanin I and (−)-chettaphanin II. Tetrahedron 2003, 59, 685–694. [Google Scholar] [CrossRef]
  6. Marcos, I.S.; Pedrero, A.B.; Sexmero, M.J.; Diez, D.; Basabe, P.; Hernández, F.A.; Broughton, H.B.; Urones, J.G. Synthesis and absolute configuration of the supposed structure of cladocoran A and B. Synlett 2002, 01, 0105–0109. [Google Scholar] [CrossRef]
  7. Marcos, I.S.; García, N.; Sexmero, M.J.; Basabe, P.; Díez, D.; Urones, J.G. Synthesis of (+)-agelasine C. A structural revision. Tetrahedron 2005, 61, 11672–11678. [Google Scholar] [CrossRef]
  8. Marcos, I.S.; Escola, M.A.; Moro, R.F.; Basabe, P.; Diez, D.; Mollinedo, F.; Urones, J.G. Synthesis of (+)-thiersindole, C. Synlett. 2007, 13, 2017–2022. [Google Scholar] [CrossRef]
  9. Sato, A.; Kurabayashi, M.; Nagahori, H.; Ogiso, A.; Mishima, H. Chettaphanin-I, a novel furanoditerpenoid. Tetrahedron Lett. 1970, 11, 1095–1098. [Google Scholar] [CrossRef]
  10. Sato, A.; Kurabayashi, M.; Ogiso, A.; Mishima, H. Chettaphanin-II, a novel furanoditerpenoid. Tetrahedron Lett. 1971, 12, 839–842. [Google Scholar] [CrossRef]
  11. Wang, G.-C.; Li, J.-G.; Li, G.-Q.; Xu, J.-J.; Wu, X.; Ye, W.-C.; Li, Y.-L. Clerodane diterpenoids from Croton crassifolius. J. Nat. Prod. 2012, 75, 2188–2192. [Google Scholar] [CrossRef]
  12. Zhang, Z.-X.; Li, H.-H.; Qi, F.-M.; Xiong, H.-Y.; Dong, L.-L.; Fan, G.-X.; Fei, D.-Q. A New halimane diterpenoid from Croton crassifolius. Bull. Korean Chem. Soc. 2014, 35, 1556–1558. [Google Scholar] [CrossRef]
  13. Kanlayavattanakul, M.; Ruangrungsi, N.; Watanabe, T.; Kawahata, M.; Therrien, B.; Yamaguchi, K.; Ishikawa, T. ent-Halimane diterpenes and a guaiane sesquiterpene from Cladogynos orientalis. J. Nat. Prod. 2005, 68, 7–10. [Google Scholar] [CrossRef]
  14. Urones, J.G.; Marcos, I.S.; Basabe, P.; Sexmero, M.J.; Carrillo, H.; Melchor, M.J. Minor diterpenoids from Halimium viscosum. Phytochemistry 1994, 37, 1359–1361. [Google Scholar] [CrossRef]
  15. Urones, J.G.; De Pascual Teresa, J.; Marcos, I.S.; Díez Martín, D.; Martín Garrido, N.; Guerra, R.A. Diterpenoids from Halimium viscosum. Phytochemistry 1987, 26, 1077–1079. [Google Scholar] [CrossRef]
  16. Khoo, S.F.; Oehlschlager, A.C.; Ourisson, G. Structure and stereochemistry of the diterpenes of Hymenaea courbaril (Caesalpinioideae) seed pod resin. Tetrahedron 1973, 29, 3379–3388. [Google Scholar] [CrossRef]
  17. Urones, J.G.; Sexmero, M.J.; Hernández, F.A.; Basabe, P.; Pedrero, A.B.; Diez, D.; Marcos, I.S. Minor Diterpenoids from Halimium viscosum. Nat. Prod. Lett. 2001, 15, 387–391. [Google Scholar] [CrossRef]
  18. Urones, J.G.; Marcos, I.S.; Sexmero, M.J.; Basabe, P.; Lithgow, A.M. ent-Halimane diterpenes from Halimium viscosum. Phytochemistry 1990, 29, 1247–1251. [Google Scholar] [CrossRef]
  19. De Pascual Teresa, J.; Urones, J.G.; Carrillo, H. Componentes del Halimium umbellatum (L.) Spach III. Ácido halímico [ent-9,1-friedolabd-1(10),13-dien-15-hidroxi-18-oico] y derivados. An. Quim. 1978, 74, 488–493. [Google Scholar]
  20. Abdel-Kader, M.; Berger, J.M.; Slebodnick, C.; Hoch, J.; Malone, S.; Wisse, J.H.; Werkhoven, M.C.M.; Mamber, S.; Kingston, D.G.I. Isolation and absolute configuration of ent-Halimane diterpenoids from Hymenaea courbaril from the suriname rain forest. J. Nat. Prod. 2002, 65, 11–15. [Google Scholar] [CrossRef]
  21. Rodilla, J.M.L.; Mendonça, D.I.D.; Ismael, M.I.G.; Figueiredo, J.A.; Silva, M.L.A.; Lopes, E. BI- and Tricyclic Diterpenoids from Halimium viscosum. Nat. Prod. Lett. 2001, 15, 401–409. [Google Scholar] [CrossRef] [PubMed]
  22. Yuan, Q.-Q.; Tang, S.; Song, W.-B.; Wang, W.-Q.; Huang, M.; Xuan, L.-J. Crassins A–H, Diterpenoids from the roots of Croton crassifolius. J. Nat. Prod. 2017, 80, 254–260. [Google Scholar] [CrossRef] [PubMed]
  23. De Pascual Teresa, J.; Urones, J.G.; Basabe, P.; Carrillo, H.; Muñoz, M.A.G.; Marcos, I.S. Diterpenoids of Halimium viscosum. Phytochemistry 1985, 24, 791–794. [Google Scholar] [CrossRef]
  24. De Mendonça, D.I.M.D.; Rodilla, J.M.L.; Lithgow, A.M.; Marcos, I.S. Hydrohalimic acids from Halimium viscosum. Phytochemistry 1997, 44, 1301–1307. [Google Scholar] [CrossRef]
  25. De Pascual Teresa, J.; Urones, J.G.; Carrillo, H.; Muñoz, M.A.G. Ácidos diterpénicos del Halimium viscosum (Wilk) P. Silva. Ácido hidrohalímico (ácido ent-9,1-friedolabd-1(10)-en-15-hidroxi-18-oico) y derivados. An. Quim. 1979, 75, 140–143. [Google Scholar]
  26. Rodilla, J.M.L.; De Mendonça, D.I.M.; Urones, J.G.; Moro, R.F. Hydroxylated diterpenoids from Halimium viscosum. Phytochemistry 1998, 49, 817–822. [Google Scholar] [CrossRef]
  27. Monteiro, A.F.; Batista, J.M.; Machado, M.A.; Severino, R.P.; Blanch, E.W.; Bolzani, V.S.; Vieira, P.C.; Severino, V.G.P. Structure and absolute configuration of diterpenoids from Hymenaea stigonocarpa. J. Nat. Prod. 2015, 78, 1451–1455. [Google Scholar] [CrossRef]
  28. Jakupovic, J.; Ellmauerer, E.; Bohlmann, F.; Whittemori, A.; Gage, D. Diterpenes from Eupatorium turbinatum. Phytochemistry 1986, 25, 2677–2680. [Google Scholar] [CrossRef]
  29. Urones, J.G.; Marcos, I.S.; Sexmero, M.J.; Basabe, P.; Lithgow, A.M. Nor-ent-halimanes from Halimium viscosum. Phytochemistry 1990, 29, 3597–3600. [Google Scholar] [CrossRef]
  30. Pinto, Â.C.; Antunes, O.A.C.; Pizzolatti, M.G.; Rumjanek, V.M. A tetranorfriedolabdane diterpene from Vellozia stipitata. Phytochemistry 1996, 42, 771–774. [Google Scholar] [CrossRef]
  31. Rijo, P.; Gaspar-Marques, C.; Simões, M.F.; Jimeno, M.L.; Rodríguez, B. Further diterpenoids from Plectranthus ornatus and P. grandidentatus. Biochem. Syst. Ecol. 2007, 35, 215–223. [Google Scholar] [CrossRef]
  32. Rijo, P.; Rodriguez, B.; Duarte, A.; Simoes, M.F. Antimicrobial properties of Plectranthus ornatus extracts, 11-acetoxyhalima-5, 13-dien-15-oic acid metabolite and its derivatives. Natur. Products J. 2011, 1, 57–64. [Google Scholar]
  33. Jakupovic, J.; Baruah, R.N.; Zdero, C.; Eid, F.; Pathak, V.P.; Chau-thi, T.V.; Bohlmann, F.; King, R.M.; Robinson, H. Further diterpenes from plants of the compositae, subtribe solidagininae. Phytochemistry 1986, 25, 1873–1881. [Google Scholar] [CrossRef]
  34. Tsichritzis, F.; Jakupovic, J. Diterpenes and other constituents from Relhania species. Phytochemistry 1990, 29, 3173–3187. [Google Scholar] [CrossRef]
  35. Del Corral, S.; Cuffini, S.L.; Cardoso, S.G.; Bortoluzzid, A.J.; Palacios, S.M. Phytotoxic halimanes isolated from Baccharis salicifolia (Ruiz & Pad.) Pers. Phytochem. Lett. 2012, 5, 280–282. [Google Scholar]
  36. Aldhaher, A.; Langat, M.; Ndunda, B.; Chirchir, D.; Midiwo, J.O.; Njue, A.; Schwikkard, S.; Carew, M.; Mulholland, D. Diterpenoids from the roots of Croton dichogamus Pax. Phytochemistry 2017, 144, 1–8. [Google Scholar] [CrossRef] [PubMed]
  37. Jakupovic, J.; Banerjee, S.; Bohlmann, F.; King, R.M.; Robinson, H. New diterpenes from Chiliotrichium rosmarinifolium and Nardophyllum lanatum. Tetrahedron 1986, 42, 1305–1313. [Google Scholar] [CrossRef]
  38. Sánchez, M.; Mazzuca, M.; Veloso, M.J.; Fernández, L.R.; Siless, G.; Puricelli, L.; Palermo, J.A. Cytotoxic terpenoids from Nardophyllum bryoides. Phytochemistry 2010, 71, 1395–1399. [Google Scholar] [CrossRef]
  39. Fiorentino, A.; D’Abrosca, B.; Pacifico, S.; Scognamiglio, M.; D’Angelo, G.; Gallicchio, M.; Chambery, A.; Monaco, P. Structure elucidation and hepatotoxicity evaluation against HepG2 human cells of neo-clerodane diterpenes from Teucrium polium L. Phytochemistry 2011, 72, 2037–2044. [Google Scholar] [CrossRef]
  40. Li, R.; Morris-Natschke, S.L.; Lee, K.-H. Clerodane diterpenes: Sources, structures, and biological activities. Nat. Prod. Rep. 2016, 33, 1166–1226. [Google Scholar] [CrossRef]
  41. Bohlmann, F.; Abraham, W.-R.; King, R.M.; Robinson, H. Diterpenes from Koanophyllon species. Phytochemistry 1981, 20, 1903–1906. [Google Scholar] [CrossRef]
  42. Zdero, C.; Bohlmann, F.; Niemeyer, H.M. Friedolabdanes and other constituents from chilean Haplopappus species. Phytochemistry 1991, 30, 3669–3677. [Google Scholar] [CrossRef]
  43. Siems, K.; Jakupovic, J.; Castro, V.; Poveda, L. Constituents of two Acalypha species. Phytochemistry 1996, 41, 851–853. [Google Scholar] [CrossRef]
  44. Du, K.; De Mieri, M.; Neuburger, M.; Zietsman, P.C.; Marston, A.; van Vuuren, S.F.; Ferreira, D.; Hamburger, M.; van der Westhuizen, J.H. Labdane and clerodane diterpenoids from Colophospermum mopane. J. Nat. Prod. 2015, 78, 2494–2504. [Google Scholar] [CrossRef] [PubMed]
  45. Zhang, Y.; Adnani, N.; Braun, D.R.; Ellis, G.A.; Barns, K.J.; Parker-Nance, S.; Guzei, I.A.; Bugni, T.S. Micromonohalimanes A and B: Antibacterial halimane-Type diterpenoids from a marine micromonospora species. J. Nat. Prod. 2016, 79, 2968–2972. [Google Scholar] [CrossRef]
  46. Ono, M.; Yamasaki, T.; Konoshita, M.; Ikeda, T.; Okawa, M.; Kinjo, J.; Yoshimitsu, H.; Nohara, T. Five New Diterpenoids, viteagnusins A—E, from the fruit of Vitex agnus-castus. Chem. Pharm. Bull. 2008, 56, 1621–1624. [Google Scholar] [CrossRef]
  47. Wang, W.-q.; Yin, Y.-p.; Jun, L.; Xuan, L.-j. Halimane-type diterpenoids from Vitex rotundifolia and their anti-hyperlipidemia activities. Phytochemistry 2018, 146, 56–62. [Google Scholar] [CrossRef]
  48. Pinto, A.C.; Antunes, O.A.C.; Rezende, C.M.; Correia, C.R.D. Minor cleisthantane and tetranorfriedolabdane from Vellozia flavicans. Phytochemistry 1995, 38, 1269–1271. [Google Scholar] [CrossRef]
  49. Kihampa, C.; Nkunya, M.H.H.; Joseph, C.C.; Magesa, S.M.; Hassanali, A.; Heydenreich, M.; Kleinpeter, E. Anti-mosquito and antimicrobial nor-halimanoids, isocoumarins and an anilinoid from Tessmannia densiflora. Phytochemistry 2009, 70, 1233–1238. [Google Scholar] [CrossRef]
  50. Nyandoro, S.S. Some rare Tanzanian plant species as sources of less common metabolites: Biomedical potential and conservation status. J. Pharmacogn. Phytochem. 2014, 3, 147–157. [Google Scholar]
  51. Kawashima, T.; Nakatsu, T.; Fukazawa, Y.; Itô, S. Diterpenic lactones of Mallotus repandus. Heterocycles 1976, 5, 227–232. [Google Scholar]
  52. Fernández-Gadea, F.; Pascual, C.; Rodríguez, B.; Savona, G. 6-epiteucrin A, a neo-clerodane diterpenoid from Teucrium chamaedrys. Phytochemistry 1983, 22, 723–725. [Google Scholar] [CrossRef]
  53. Fujita, E.; Uchida, I.; Fujita, T.; Masaki, N.; Osaki, K. Teucvin, a novel furanoid norditerpene from Teucrium viscidum var. Miquelianum. Chem. Commun. 1973, 793–794. [Google Scholar] [CrossRef]
  54. Fujita, E.; Uchida, I.; Fujita, T. Terpenoids. Part XXXII. Structure and stereochemistry of teucvin, a novel norclerodane-type diterpene from Teucrium viscidum var. Miquelianum. Perkin Trans. 1 1974, 1547–1555. [Google Scholar] [CrossRef]
  55. Mbwambo, Z.H.; Foubert, K.; Chacha, M.; Kapingu, M.C.; Magadula, J.J.; Moshi, M.M.; Lemière, F.; Goubitz, K.; Fraanje, J.; Peschar, R.; Vlietinck, A.; Apers, S.; Pieters, L. New furanoditerpenoids from Croton jatrophoides. Planta Med. 2009, 75, 262–264. [Google Scholar] [CrossRef]
  56. Marcos, I.S.; Pedrero, A.B.; Sexmero, M.J.; Diez, D.; Basabe, P.; Hernández, F.A.; Urones, J.G. Synthesis and absolute configuration of three natural ent-halimanolides with biological activity. Tetrahedron Lett. 2003, 44, 369–372. [Google Scholar] [CrossRef]
  57. Marcos, I.S.; Conde, A.; Moro, R.; Basabe, P.; Díez, D.; Mollinedo, F.; Urones, J. Synthesis of an ent-Halimanolide from ent-Halimic Acid. Molecules 2008, 13, 1120–1134. [Google Scholar] [CrossRef]
  58. Marcos, I.S.; Gonzalez, J.L.; Sexmero, M.J.; Díez, D.; Basabe, P.; Williams, D.J.; Simmonds, M.S.J.; Urones, J.G. Diterpenic α- and β-hydroxybutanolides with antifeedant activity: Semisynthesis and absolute configuration. Tetrahedron Lett. 2000, 41, 2553–2557. [Google Scholar] [CrossRef]
  59. Marcos, I.S.; Escola, M.A.; Moro, R.F.; Basabe, P.; Diez, D.; Sanz, F.; Mollinedo, F.; de la Iglesia-Vicente, J.; Sierra, B.G.; Urones, J.G. Synthesis of novel antitumoral analogues of dysidiolide from ent-halimic acid. Bioorg. Med. Chem. 2007, 15, 5719–5737. [Google Scholar] [CrossRef]
  60. Marcos, I.S.; Pedrero, A.B.; Sexmero, M.J.; Diez, D.; Basabe, P.; García, N.; Moro, R.F.; Broughton, H.B.; Mollinedo, F.; Urones, J.G. Synthesis of Bioactive Sesterterpenolides from ent-Halimic Acid. 15-Epi-ent-cladocoran A and B. J. Nat. Prod. 2003, 68, 7496–7504. [Google Scholar]
  61. Gil-Mesón, A.; Roncero, A.; Tobal, I.; Basabe, P.; Díez, D.; Mollinedo, F.; Marcos, I.S. Synthesis of bioconjugate sesterterpenoids with phospholipids and polyunsaturated fatty acids. Molecules 2016, 21, 47. [Google Scholar] [CrossRef]
  62. Marcos, I.S.; Sexmero, M.; Hernández, F.; Corrales, M.; Basabe, P.; Díez, D.; Urones, J.G. Synthetic studies towards the ent-Labdane diterpenoids: rearrangement of ent-Halimanes. Molecules 2006, 11, 792–807. [Google Scholar] [CrossRef]
  63. Marcos, I.S.; García, N.; Sexmero, M.J.; Hernández, F.A.; Escola, M.A.; Basabe, P.; Díez, D.; Urones, J.G. Synthetic studies towards picrasane quassinoids. Tetrahedron 2007, 63, 2335–2350. [Google Scholar] [CrossRef]
  64. Marcos, I.S.; Martínez, B.; Sexmero, M.J.; Diez, D.; Basabe, P.; Urones, J.G. Chemistry of ent-Halimic acid: synthesis of [4.3.3] propellanes. Synthesis 2006, 3865–3873. [Google Scholar] [CrossRef]
  65. Marcos, I.S.; Conde, A.; Moro, R.F.; Basabe, P.; Díez, D.; Urones, J.G. Synthesis of quinone/hydroquinone sesquiterpenes. Tetrahedron 2010, 66, 8280–8290. [Google Scholar] [CrossRef]
  66. Marcos, I.S.; Moro, R.F.; Costales, I.; Basabe, P.; Díez, D.; Mollinedo, F.; Urones, J.G. Synthesis of 12-epi-ent-polyalthenol an antitumor indole sesquiterpene alkaloid. Tetrahedron 2012, 68, 7932–7940. [Google Scholar] [CrossRef]
  67. Marcos, I.S.; Moro, R.F.; Costales, I.; Basabe, P.; Díez, D.; Mollinedo, F.; Urones, J.G. Biomimetic synthesis of an antitumor indole sesquiterpene alkaloid, 12-epi-ent-pentacyclindole. Tetrahedron 2013, 69, 7285–7289. [Google Scholar] [CrossRef]
  68. Marcos, I.S.; Moro, R.F.; Costales, I.; Basabe, P.; Díez, D.; Gil, A.; Mollinedo, F.; Pérez-de la Rosa, F.; Pérez-Roth, E.; Padrón, J.M. Synthesis and biological activity of polyalthenol and pentacyclindole analogues. Eur. J. Med. Chem. 2014, 73, 265–279. [Google Scholar] [CrossRef]
  69. Marcos, I.S.; Moro, R.F.; Costales, I.; Escola, M.A.; Basabe, P.; Díez, D.; Urones, J.G. Synthesis of hexahydrocarbazoles by cyclisation of 3-(but-3-enyl) indole derivatives. Tetrahedron 2009, 65, 10235. [Google Scholar] [CrossRef]
  70. Bestmann, H.J. Phosphacumulene ylides and phosphaallene ylides [New synthetic methods (19)]. Angew. Chem. Int. Ed. 1977, 16, 349–364. [Google Scholar] [CrossRef]
  71. Boukouvalas, J.; Lachance, N. A Mild, Efficient and general method for the synthesis of Trialkylsilyl (Z)-4-Oxo-2-alkenoates and γ-hydroxybutenolides. Synlett 1998, 1998, 31–32. [Google Scholar] [CrossRef]
  72. Rice, L.E.; Boston, M.C.; Finklea, H.O.; Suder, B.J.; Frazier, J.O.; Hudlicky, T. Regioselectivity in the reformatskii reaction of 4-bromocrotonate. role of the catalyst and the solvent in the normal vs. abnormal modes of addition to carbonyl substrates. J. Nat. Prod. 1984, 49, 1845–1848. [Google Scholar]
  73. LeGoff, E. Cyclopropanes from an easily prepared, highly active Zinc—Copper couple, dibromomethane, and olefins. J. Nat. Prod. 1964, 29, 2048–2050. [Google Scholar] [CrossRef]
  74. Fontana, A.; Ciavatta, M.L.; Cimino, G. Cladocoran A and B: Two novel γ-hydroxybutenolide sesterterpenes from the mediterranean coral Cladocora cespitosa. J. Org. Chem. 1998, 63, 2845–2852. [Google Scholar] [CrossRef]
  75. Gunasekera, S.P.; McCarthy, P.J.; Kelly-Borges, M.; Lobkovsky, E.; Clardy, J. Dysidiolide: A novel protein phosphatase inhibitor from the caribbean sponge Dysidea etheria de laubenfels. J. Am. Chem. Soc. 1996, 118, 8759–8760. [Google Scholar] [CrossRef]
  76. Corey, E.J.; Roberts, B.E. Total Synthesis of Dysidiolide. J. Am. Chem. Soc. 1997, 119, 12425–12431. [Google Scholar] [CrossRef]
  77. Takahashi, M.; Dodo, K.; Sugimoto, Y.; Aoyagi, Y.; Yamada, Y.; Hashimoto, Y.; Shirai, R. Synthesis of the novel analogues of dysidiolide and their structure–activity relationship. Bioorg. Med. Chem. Lett. 2000, 10, 2571–2574. [Google Scholar] [CrossRef]
  78. Draetta, G.; Eckstein, J. Cdc25 protein phosphatases in cell proliferation. Biochim Biophys Acta 1997, 1332, M53–M63. [Google Scholar] [CrossRef]
  79. Magnuson, S.R.; Sepp-Lorenzino, L.; Rosen, N.; Danishefsky, S.J. A concise total synthesis of dysidiolide through application of a dioxolenium-mediated diels−Alder Reaction. J. Am. Chem. Soc. 1998, 120, 1615–1616. [Google Scholar] [CrossRef]
  80. Boukouvalas, J.; Cheng, Y.-X.; Robichaud, J. Total synthesis of (+)-dysidiolide. J. Org. Chem. 1998, 63, 228–229. [Google Scholar] [CrossRef]
  81. Brohm, D.; Metzger, S.; Bhargava, A.; Müller, O.; Lieb, F.; Waldmann, H. Natural Products Are Biologically Validated Starting Points in Structural Space for Compound Library Development: solid-phase synthesis of dysidiolide-derived phosphatase inhibitors. Angew. Chem. Int. Ed. 2002, 41, 307–311. [Google Scholar] [CrossRef]
  82. Kernan, M.R.; Faulkner, D.J. Regioselective oxidation of 3-alkylfurans to 3-alkyl-4-hydroxybutenolides. J. Nat. Prod. 1988, 53, 2773–2776. [Google Scholar] [CrossRef]
  83. Bradley, M.O.; Webb, N.L.; Anthony, F.H.; Devanesan, P.; Witman, P.A.; Hemamalini, S.; Chander, M.C.; Baker, S.D.; He, L.; Horwitz, S.B.; Swindell, C.S. Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel. Clin. Can. Res. 2001, 7, 3229–3238. [Google Scholar]
  84. Kuznetsova, L.; Chen, J.; Sun, L.; Wu, X.; Pepe, A.; Veith, J.M.; Pera, P.; Bernacki, R.J.; Ojima, I. Syntheses and evaluation of novel fatty acid-second-generation taxoid conjugates as promising anticancer agents. Bioorg. Med. Chem. Lett. 2006, 16, 974–977. [Google Scholar] [CrossRef]
  85. Pedersen, P.J.; Christensen, M.S.; Ruysschaert, T.; Linderoth, L.; Andresen, T.L.; Melander, F.; Mouritsen, O.G.; Madsen, R.; Clausen, M.H. Synthesis and biophysical characterization of chlorambucil anticancer ether lipid prodrugs. J. Med. Chem. 2009, 52, 3408–3415. [Google Scholar] [CrossRef]
  86. Faustino, M.; Consuelo, G.; Sonsoles, M.-S.; Federico, G. ET-18-OCH3 (Edelfosine): A selective antitumor lipid targeting apoptosis through intracellular activation of Fas/CD95 death receptor. Curr. Med. Chem. 2004, 11, 3163–3184. [Google Scholar]
  87. VanderRoest, J.M.; Grieco, P.A. Total synthesis of (±)-bruceantin. J. Nat. Prod. 1993, 115, 5841–5842. [Google Scholar] [CrossRef]
  88. Marcos, I.S.; Conde, A.; Moro, R.F.; Basabe, P.; Diez, D.; Urones, J.G. Quinone/Hydroquinone sesquiterpenes. Mini-Rev. Org. Chem. 2010, 7, 230–254. [Google Scholar] [CrossRef]
  89. Barton, D.H.R.; Bridon, D.; Zardb, S.Z. The invention of radical chain reactions: Part XIV. A decarboxylative radical addition to quinones. Tetrahedron 1987, 43, 5307–5314. [Google Scholar] [CrossRef]
  90. Ling, T.; Poupon, E.; Rueden, E.J.; Theodorakis, E.A. Synthesis of (−)-Ilimaquinone via a radical decarboxylation and quinone addition reaction. Org. Lett. 2002, 4, 819–822. [Google Scholar] [CrossRef]
  91. Rosemeyer, H. The chemodiversity of purine as a constituent of natural products. Chem. Biodivers. 2004, 1, 361–401. [Google Scholar] [CrossRef]
  92. Nakamura, H.; Wu, H.; Ohizumi, Y.; Hirata, Y. Agelasine-A, -B, -C and -D, novel bicyclic diterpenoids with a 9-methyladeninium unit possessing inhibitory effects on Na, K-atpase from the okinawa sea sponge Agelas sp.1). Tetrahedron Lett. 1984, 25, 2989–2992. [Google Scholar] [CrossRef]
  93. Hattori, T.; Adachi, K.; Shizuri, Y. New agelasine compound from the marine sponge Agelas mauritiana as an antifouling substance against macroalgae. J. Nat. Prod. 1997, 60, 411–413. [Google Scholar] [CrossRef]
Molecules 24 02120 g001 550
Figure 1. The methylene-cycloalkylacetate (MCA) scaffold for novel neurotrophic agents and ent-halimic acid, the halimane reference compound.
Figure 1. The methylene-cycloalkylacetate (MCA) scaffold for novel neurotrophic agents and ent-halimic acid, the halimane reference compound.
Molecules 24 02120 g001
Molecules 24 02120 g002 550
Figure 2. Halimane diterpenoids with the annular double bond in Ring A.
Figure 2. Halimane diterpenoids with the annular double bond in Ring A.
Molecules 24 02120 g002
Molecules 24 02120 g003 550
Figure 3. Halimane diterpenoids with the annular double bond in Ring B.
Figure 3. Halimane diterpenoids with the annular double bond in Ring B.
Molecules 24 02120 g003
Molecules 24 02120 g004 550
Figure 4. Secohalimanes and 4-enes derivatives.
Figure 4. Secohalimanes and 4-enes derivatives.
Molecules 24 02120 g004
Molecules 24 02120 g005 550
Figure 5. Ent-halimanolides, chettaphanins, and sesterterpenolides obtained from 2.
Figure 5. Ent-halimanolides, chettaphanins, and sesterterpenolides obtained from 2.
Molecules 24 02120 g005
Molecules 24 02120 g006 550
Figure 6. Hybrid and rearranged compounds, sesquiterpene-quinones/hydroquinone, and terpene alkaloids obtained from 2.
Figure 6. Hybrid and rearranged compounds, sesquiterpene-quinones/hydroquinone, and terpene alkaloids obtained from 2.
Molecules 24 02120 g006
Molecules 24 02120 sch001 550
Scheme 1. Synthesis of ent-halimanolides 90–92 from 2. (a) NaH, MeI, THF (92%); (b) LAH, Et2O (96%); (c) TPAP, NMO (91%); (d) diethylene glycol, NH2NH2/H2O, KOH, 175–230 °C, 23 h (85%); (e) m-CPBA (92%); (f) H5IO6, THF, H2O (91%); (g) LDA, TMSCl, THF, −78 °C (97%); (h) OsO4, NMO, t-BuOH/THF/H2O (7:2:1) (96%); (i) Ph3P=C= C=O, C6H6 (91%); (j) I2/C6H6 (10−2M) (99%); (k) LDA, TBSTf, THF, −78 °C (94%); (l) m-CPBA (77%); (m) HI/C6H6 (5 × 10−2 M) (99%).
Scheme 1. Synthesis of ent-halimanolides 90–92 from 2. (a) NaH, MeI, THF (92%); (b) LAH, Et2O (96%); (c) TPAP, NMO (91%); (d) diethylene glycol, NH2NH2/H2O, KOH, 175–230 °C, 23 h (85%); (e) m-CPBA (92%); (f) H5IO6, THF, H2O (91%); (g) LDA, TMSCl, THF, −78 °C (97%); (h) OsO4, NMO, t-BuOH/THF/H2O (7:2:1) (96%); (i) Ph3P=C= C=O, C6H6 (91%); (j) I2/C6H6 (10−2M) (99%); (k) LDA, TBSTf, THF, −78 °C (94%); (l) m-CPBA (77%); (m) HI/C6H6 (5 × 10−2 M) (99%).
Molecules 24 02120 sch001
Molecules 24 02120 sch002 550
Scheme 2. Synthesis of ent-halimanolide derivatives 97–104 and 109. (a) Rose Bengal, hυ, O2, then NaBH4; (b) BH3, THF, then H2O2/NaOH; (51%, two steps); (c) 1. 2,2 DMP, CSA; 2. PDC, DMF (83%); (d) 1. PhCHO, CSA; 2. PDC, DMF (75%); (e) p-TsOH, MeOH (93%); (f) p-TsOH, MeOH (94%); (g)1. m-CPBA; 2. H5IO6 (56%) (h) 1. LDA/TMSCl, then m-CPBA (85%); 2. (MeO)2CH2/P2O5 (81%); (i) 1. Zn–Cu/I2/BrCH2COOMe; 2. HCl, MeOH (79%).
Scheme 2. Synthesis of ent-halimanolide derivatives 97–104 and 109. (a) Rose Bengal, hυ, O2, then NaBH4; (b) BH3, THF, then H2O2/NaOH; (51%, two steps); (c) 1. 2,2 DMP, CSA; 2. PDC, DMF (83%); (d) 1. PhCHO, CSA; 2. PDC, DMF (75%); (e) p-TsOH, MeOH (93%); (f) p-TsOH, MeOH (94%); (g)1. m-CPBA; 2. H5IO6 (56%) (h) 1. LDA/TMSCl, then m-CPBA (85%); 2. (MeO)2CH2/P2O5 (81%); (i) 1. Zn–Cu/I2/BrCH2COOMe; 2. HCl, MeOH (79%).
Molecules 24 02120 sch002
Molecules 24 02120 sch003 550
Scheme 3. Synthesis of ent-halimanolide 112 from 2. (a) OsO4, NMO, t-BuOH/THF/H2O (7:2:1); (b) Pb(AcO)4, C6H6, 20 min (94%, two steps); (c) Na2CrO4, Ac2O/AcOH, NaOAc, C6H6 (64%); (d) MePPh3Br, NaHMDS, THF, −78 °C (94%); (e) p-TsOH, C6H6, 60 °C (96%); (f) (CH2OH)2, p-TsOH, C6H6, Dean Stark (97%); (g) (1) OsO4, NMO, t-BuOH, THF, H2O; (2) Pb(AcO)4, C6H6 (96%, two steps); (h) 3-bromofuran, n-BuLi, THF (117: 54%, 118: 39%); (i) Ac2O, pyridine (98%); (j) HCl 2 M, EtOH (96%); (k) Na2CO3, MeOH, 2 h (96%); (l) NaBH4, EtOH (298: 38%, 297: 43%); (m) TPAP, NMO, DCM, rt, 50 min (92%).
Scheme 3. Synthesis of ent-halimanolide 112 from 2. (a) OsO4, NMO, t-BuOH/THF/H2O (7:2:1); (b) Pb(AcO)4, C6H6, 20 min (94%, two steps); (c) Na2CrO4, Ac2O/AcOH, NaOAc, C6H6 (64%); (d) MePPh3Br, NaHMDS, THF, −78 °C (94%); (e) p-TsOH, C6H6, 60 °C (96%); (f) (CH2OH)2, p-TsOH, C6H6, Dean Stark (97%); (g) (1) OsO4, NMO, t-BuOH, THF, H2O; (2) Pb(AcO)4, C6H6 (96%, two steps); (h) 3-bromofuran, n-BuLi, THF (117: 54%, 118: 39%); (i) Ac2O, pyridine (98%); (j) HCl 2 M, EtOH (96%); (k) Na2CO3, MeOH, 2 h (96%); (l) NaBH4, EtOH (298: 38%, 297: 43%); (m) TPAP, NMO, DCM, rt, 50 min (92%).
Molecules 24 02120 sch003
Molecules 24 02120 sch004 550
Scheme 4. Synthesis of chettaphanins I and II from 2. (a) OsO4, NMO, t-BuOH/THF/H2O (7:2:1), 24 h (99%); (b) LTA, C6H6, 20 min (95%); (c) Na2CrO4, Ac2O/AcOH, NaOAc, benzene, 55°C, 15 h (64%); (d) UHP/TFAA, CH2Cl2, 60 min (61%); (e) ethylene glycol, p-TsOH, benzene, reflux, 8 h (76%); (f) K2CO3, MeOH, 3%, 60 min (99%); (g) PDC, DMF, 3 h (98%); (h) 3-bromofurane, n-BuLi, THF, −78°C, 20 min (90%); (i) TPAP, NMO, CH2Cl2, 45 min (93%); (j) p-TsOH, acetone, 5 h (72%); (k) m-CPBA, Cl2CH2, 12 h, rt; (m) p-TsOH, acetone, 5 h, rt or HClO4, 3 h, rt.
Scheme 4. Synthesis of chettaphanins I and II from 2. (a) OsO4, NMO, t-BuOH/THF/H2O (7:2:1), 24 h (99%); (b) LTA, C6H6, 20 min (95%); (c) Na2CrO4, Ac2O/AcOH, NaOAc, benzene, 55°C, 15 h (64%); (d) UHP/TFAA, CH2Cl2, 60 min (61%); (e) ethylene glycol, p-TsOH, benzene, reflux, 8 h (76%); (f) K2CO3, MeOH, 3%, 60 min (99%); (g) PDC, DMF, 3 h (98%); (h) 3-bromofurane, n-BuLi, THF, −78°C, 20 min (90%); (i) TPAP, NMO, CH2Cl2, 45 min (93%); (j) p-TsOH, acetone, 5 h (72%); (k) m-CPBA, Cl2CH2, 12 h, rt; (m) p-TsOH, acetone, 5 h, rt or HClO4, 3 h, rt.
Molecules 24 02120 sch004
Molecules 24 02120 g007 550
Figure 7. Chemical structures for sesterterpenolides and ent-halimic acid.
Figure 7. Chemical structures for sesterterpenolides and ent-halimic acid.
Molecules 24 02120 g007
Molecules 24 02120 sch005 550
Scheme 5. Synthesis of sesterterpenolides from 2.
Scheme 5. Synthesis of sesterterpenolides from 2.
Molecules 24 02120 sch005
Molecules 24 02120 sch006 550
Scheme 6. Synthesis of sesterterpenolides analogues 135–138 from 2.
Scheme 6. Synthesis of sesterterpenolides analogues 135–138 from 2.
Molecules 24 02120 sch006
Molecules 24 02120 g008 550
Figure 8. Synthesized sesterterpenolides hybrid compounds.
Figure 8. Synthesized sesterterpenolides hybrid compounds.
Molecules 24 02120 g008
Molecules 24 02120 sch007 550
Scheme 7. Tetranorlabdanes synthesized from 2.
Scheme 7. Tetranorlabdanes synthesized from 2.
Molecules 24 02120 sch007
Molecules 24 02120 sch008 550
Scheme 8. Synthesis of abeopicrasane 147 from 2.
Scheme 8. Synthesis of abeopicrasane 147 from 2.
Molecules 24 02120 sch008
Molecules 24 02120 sch009 550
Scheme 9. Synthesis of propellane terpenoids from 2.
Scheme 9. Synthesis of propellane terpenoids from 2.
Molecules 24 02120 sch009
Molecules 24 02120 sch010 550
Scheme 10. Synthesis of quinones/hydroquinones sesquiterpenes from 2.
Scheme 10. Synthesis of quinones/hydroquinones sesquiterpenes from 2.
Molecules 24 02120 sch010
Molecules 24 02120 g009 550
Figure 9. First proposed structures for agelasine C (162) and epi-agelasine C (163).
Figure 9. First proposed structures for agelasine C (162) and epi-agelasine C (163).
Molecules 24 02120 g009
Molecules 24 02120 sch011 550
Scheme 11. Synthesis of 164 from 2.
Scheme 11. Synthesis of 164 from 2.
Molecules 24 02120 sch011
Molecules 24 02120 g010 550
Figure 10. Revised structures for (-)-agelasine C and epi-agelasine C.
Figure 10. Revised structures for (-)-agelasine C and epi-agelasine C.
Molecules 24 02120 g010
Molecules 24 02120 sch012 550
Scheme 12. Synthesis of (+)-thiersindole C from 2.
Scheme 12. Synthesis of (+)-thiersindole C from 2.
Molecules 24 02120 sch012
Molecules 24 02120 sch013 550
Scheme 13. Retrosynthesis of 12-epi-ent-pentacyclindole, 174, from 2.
Scheme 13. Retrosynthesis of 12-epi-ent-pentacyclindole, 174, from 2.
Molecules 24 02120 sch013
Molecules 24 02120 g011 550
Figure 11. Polyalthenol and pentacyclindole structures.
Figure 11. Polyalthenol and pentacyclindole structures.
Molecules 24 02120 g011
Molecules 24 02120 g012 550
Figure 12. Sesquiterpenylindoles synthesized from 2.
Figure 12. Sesquiterpenylindoles synthesized from 2.
Molecules 24 02120 g012
Table
Table 1. Halim-1(10)-enes.
Table 1. Halim-1(10)-enes.
Natural SourceActivityRef.
Halim-1(10)-enes
Chettaphanin I, 1Adenochlaena siamensis (Syn. of Cladogynos orientalis)
Croton crassifolius		 [5,9,10,11,12,13]
Ent-halimic acid methyl ester, 2Halimium viscosum (Villarino de los Aires, V.A.) [14,15]
3H. viscosum (V.A.) [14,15]
4H. viscosum (V.A.) [14]
5H. viscosum (V.A.) [14]
6H. viscosum (V.A.) [14]
7H. viscosum (V.A.) [14]
8H. viscosum (V.A.)
Hymenaea courbaril		 [15,16]
9H. viscosum (V.A.) [14,15]
10H. viscosum (V.A.) [15]
11H. viscosum (V.A.) [15]
12H. viscosum (V.A.) [17]
13H. viscosum (V.A.) [18]
14H. viscosum (V.A.) [18]
15H. viscosum (V.A.) [14]
16H. viscosum (V.A.) [14]
17H. viscosum (V.A.) [18,19]
18H. viscosum (V.A.) [18,19]
19H. viscosum (V.A.) [18]
20H. viscosum (V.A.) [18]
21H. viscosum (V.A.) [18]
13R-Hydroxy-ent-halima-1(10),14-dien-18-oic acid, 22Hymenaea courbarilA2780 human ovarian cell line (IC50 > 40 μg/mL)[20]
2S,13R-Dihydroxy-ent-halima-1(10),14-dien-18-oic acid, 23H. courbaril [20]
2-Oxo-13R-hydroxy-ent-halima-1(10),14-dien-18-oic acid, 24H. courbaril [20]
25H. viscosum (Celorico da Beira, C.B.) [21]
Crassifoliusin A, 26Croton crassifoliusNot cytotoxic (HepG2, SGC-7901 and K562)[12]
Crassin D, 27C. crassifoliusNot cytotoxic (HL-60, and A549)[22]
28Cladogynos orientalisNot cytotoxic/NCI-H187),
not antitubercular (Mycobacterium tuberculosis H37Ra)		[13]
29Hymenaea courbaril [16]
30Halimium viscosum (La Fregeneda, L.F.) [23]
31H. viscosum (V.A. and L.F.) [14,23]
13R-Methyl-15-methoxy-ent-halim-1(10)-en-18-oate, 32H. viscosum (L.F. and C.B.) [23,24]
33H. viscosum (L.F. and C.B.) [24,25]
34H. viscosum (L.F. and C.B.) [24]
35Hymenaea courbaril [16]
36H. viscosum (C.B.) [24]
37H. viscosum (C.B.) [24]
Crassifolin C, 38Croton crassifoliusHSV-1 (IC50 50 μg/mL)[11]
39H. viscosum (L.F. and C.B.) [23,26]
18-Hydroxy-ent-halima-1(10),13E-dien-15-oic acid, 40Hymenaea stigonocarpa [27]
41Eupatorium turbinatum (Syn. of Chromolaena bigelovii) [28]
42Halimium viscosum [15,29]
43H. viscosum [17]
44H. viscosum [15,29]
45H. viscosum [29]
46H. viscosum [29]
47Vellozia stipitata [30]
Table
Table 2. Halim-5-enes.
Table 2. Halim-5-enes.
Natural SourceActivityRef.
Ent-halim-5-enes
11R-Acetoxy-ent-halima-5,13E-dien-15-oic acid, 48Plectranthus ornatusEnterococcus faecalis ATCC 51,299 MIC 15.63
Staphylococcus aureus CIP 106,760 MIC 15.63		[31,32]
49Haplopappus paucidentatus (Syn. of H. glutinosus) [33]
50Relhania corymbosa
R. squarrosa (Syn. of Oedera squarrosa)		 [34]
51R. corymbosa
R. squarrosa		 [34]
Salicifolic acid, 52Baccharis salicifolia (Syn. of B. salicina)Germination inhibition of Panicum miliaceum (ECg50 1.9/mM) and Raphanus sativum (ECg50 4.6/mM)[35]
Crothalimene B, 53Croton dichogamus [36]
3α-Hydroxy-5,6-didehydrochiliolide, 54Chiliotrichum rosmarinifolium
Nardophyllum bryoides		Murine lung adenocarcinoma cells (MLAC) LM3 (ID50 40 μM)
Human ductal pancreatic carcinoma (HDPC) PANC1 (ID50 0.3μM)		[37,38]
Teupolin VIII, 55Teucrium poliumHuman hepatoblastoma cells HepG2 (cell viability inhibition, 6.86% 100mM)[39,40]
Teupolin VII, 56T. poliumHPC HepG2. CVI, 6.35% 100mM)[39]
Halim-5-enes
Koanophyllic acid B, 57Koanophyllon conglobatum [41]
58Haplopappus pulchellus [42]
59H. pulchellus [42]
60H. pulchellus [42]
61H. pulchellus [42]
62H. pulchellus [42]
63H. pulchellus [42]
Koanophyllic acid A, 64Koanophyllon conglobatum [41]
65Acalypha macrostachya [43]
66A. macrostachya [43]
67Colophospermum mopaneKlebsiella pneumoniae ATCC 13,883 (MIC 62.5 μg/mL)
Escherichia coli ATCC 8739 (MIC 125 μg/mL)
Enterococcus faecalis ATCC 29,212 (MIC 62.5 μg/mL)
Staphylococcus aureus ATCC 25,923 (MIC 93.7 μg/mL)		[44]
Koanophyllic acid D, 68Koanophyllon conglobatum [41]
Koanophyllic acid C, 69K. conglobatum [41]
Micromonohalimane A, 70Micromonospora sp.Methicillin-resistant Staphylococcus aureus (MRSA) ATCC 33,591 (MIC > 200 μg/mL)[45]
Micromonohalimane B, 71Micromonospora sp.(MRSA) ATCC 33,591 (MIC 40 μg/mL)[45]
8-Epi-halim-5-enes
Viteagnusin A 72Vitex agnus-castus [46]
Viterofolin D, 73V. rotundifolia [47]
Viterofolin E, 74V. rotundifolia [47]
75Vellozia stipitata [30]
76V. flavicans (Syn. of V. squamata) [48]
77V. flavicans [48]
Table
Table 3. Secohalimanes and 4-enes.
Table 3. Secohalimanes and 4-enes.
Natural SourceActivityRef.
Secohalimanes
Tessmannic acid, 78Tessmannia densifloraStaphylococcus aureus, 11-20 mm
Larvicidal activity Anophelles gambiae (LC50 48 h, 34 ppm)		[49,50]
Tessmannic acid methyl ester, 79T. densifloraLarvicidal activity Anophelles gambiae (LC50 48 h, 92 ppm)[49,50]
80T. densiflora [49,50]
81T. densiflora [49,50]
Secochiliotrin methyl ester, 82Chiliotrichum rosmarinifolium
Nardophyllum lanatum		 [37]
Secochiliolide acid, 83C. rosmarinifolium
N. lanatum
N. bryoides		(MLAC) LM3 (ID50 28 μM)
(HDPC) PANC1 (ID50 20 μM)		[37,38]
Secochiliolide acid methyl ester, 84C. rosmarinifolium
N. bryoides		(MLAC) LM3 (ID50 14.1 μM)
(HDPC) PANC1 (ID50 31.6 μM)		[37,38]
19-Hydroxysecochiliolide acid, 85N. lanatum [37]
19-Hydroxysecochiliolide acid methyl ester, 86N. lanatum [37]
Secochiliolide aldehyde, 87Chiliotrichum rosmarinifolium [37]
88Nardophyllum bryoides(MLAC) LM3 (ID50 20.0 μM)
(HDPC) PANC1 (ID50 25.1 μM)		[38]
Teucvin (Mallotucin A), 89Teucrium viscidum
Mallotus repandus
Teucrium chamaedrys		 [51,52,53,54,55]

Share and Cite

MDPI and ACS Style

Tobal, I.E.; Roncero, A.M.; Moro, R.F.; Díez, D.; Marcos, I.S. The Methylene-Cycloalkylacetate (MCA) Scaffold in Terpenyl Compounds with Potential Pharmacological Activities. Molecules 2019, 24, 2120. https://doi.org/10.3390/molecules24112120

AMA Style

Tobal IE, Roncero AM, Moro RF, Díez D, Marcos IS. The Methylene-Cycloalkylacetate (MCA) Scaffold in Terpenyl Compounds with Potential Pharmacological Activities. Molecules. 2019; 24(11):2120. https://doi.org/10.3390/molecules24112120

Chicago/Turabian Style

Tobal, Ignacio E., Alejandro M. Roncero, Rosalina F. Moro, David Díez, and Isidro S. Marcos. 2019. "The Methylene-Cycloalkylacetate (MCA) Scaffold in Terpenyl Compounds with Potential Pharmacological Activities" Molecules 24, no. 11: 2120. https://doi.org/10.3390/molecules24112120

Article Metrics

Back to TopTop